KOMBIGLYZE XR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Nov 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KOMBIGLYZE XR is a fixed-dose combination oral tablet containing saxagliptin and metformin in extended-release formulation, approved by FDA in November 2010. The product is indicated for type 2 diabetes management. It combines a DPP-4 inhibitor with a biguanide to improve glycemic control in diabetic patients.
$19MPart D
LOE Approaching1.2 years to LOEProduct approaching loss of exclusivity within 1.2 years; brand team focus shifting toward managed decline and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Korean Post-marketing Surveillance for Kombiglyze XR®
Started Nov 2012
755 enrolled
Diabetes Mellitus, Type 2
Career Relevance
With zero linked job openings and imminent LOE, KOMBIGLYZE XR offers limited career growth opportunities; roles remaining are defensive in nature, focused on managed decline and payer negotiations. Professionals assigned to this product should expect portfolio consolidation and may need to transition to growth-stage pipeline assets within 12–24 months.
Brand Manager
Worked on KOMBIGLYZE XR at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.